High-Dose IV Iron Reduces Myocardial Infarction in Hemodialysis
Until now, no other treatment has been shown to reduce heart attack risk in patients on dialysis.
Anemia
ANEMIA
Review: Intravenous Iron May Increase Infection Risk
The benefits of treating anemia may need to be balanced against the risk of developing infection, according to investigators.
Low Selenium Levels Linked With Poor Response to ESAs in Hemodialysis
Previous studies indicate that selenium and selenoproteins are involved in erythropoiesis.
Daprodustat Has Efficacy Similar to ESAs for Renal Anemia
Daprodustat is as effective as erythropoiesis-stimulating agents in treating anemia in patients with dialysis-dependent and nondialysis-dependent chronic kidney disease.
Post-Transplantation Anemia Linked With Adverse Outcomes
Clinicians should screen kidney transplant recipients for post-transplantation anemia and carefully weigh the potential risks and benefits of treatment.
Functional Iron Deficiency Linked to CV Disease, Mortality
Significant associations seen for functional iron deficiency with coronary heart disease, cardiovascular mortality, all-cause mortality
Iron Status, FGF23 Tied With Poor Cardiovascular, Kidney Outcomes in CKD
Emerging data demonstrate that iron is an important regulator of FGF23.
BUN Better Indicates Anemia Risk in NDD-CKD, Study Suggests
Blood urea nitrogen (BUN) in NDD-CKD represents nitrogenous uremic toxin accumulation that could be involved in anemia of CKD.
Study: Erythropoietin Not Associated With Increased Stroke Risk in Hemodialysis
The factors that may account for any excess stroke risk among ESA users remain unclear.
FDA Denies Approval of Roxadustat for Anemia in CKD
The FDA noted that the application could not be approved in its present form and had requested an additional clinical study be conducted.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Anemia
Loading... 
Loading...